U.S. health officials have determined that untreated water used by a Florida cucumber grower is one likely source of salmonella poisoning that sickened nearly 450 people this spring. Still, that grower didn’t supply all the cucumbers that were linked to salmonella contamination, the U.S. Food and Drug Administration (FDA) noted in a recent health update. During their…  read on >  read on >

Mounjaro outperforms Ozempic in helping people lose weight, a new study shows. People taking tirzepatide (Mounjaro, Zepbound) dropped significantly more pounds than those taking semaglutide (Ozempic, Wegovy), researchers reported July 8 in the journal JAMA Internal Medicine. “Individuals with overweight or obesity treated with tirzepatide were significantly more likely to achieve clinically meaningful weight loss…  read on >  read on >

In yet another finding that touts the health benefits of wildly popular weight-loss medications like Wegovy and Ozempic, scientists report that taking the drugs may help reduce the risk of some cancers. In a study published July 5 in JAMA Network Open, researchers found people with type 2 diabetes who were being treated with a class of…  read on >  read on >

Researchers have identified a gene that can trigger obesity, behavior problems and postpartum depression when missing or damaged. The finding could lead to new treatments for postpartum depression and overeating: The study in mice suggests the so-called “love hormone” — oxytocin — may ease symptoms.  Obesity and postpartum depression are major health problems worldwide. The…  read on >  read on >

A regulation allowing the use of brominated vegetable oil in food was revoked Tuesday by the U.S. Food and Drug Administration after the agency concluded the additive was unsafe for human consumption. Brominated vegetable oil (BVO) contains bromine, which is found in fire retardants. Small quantities of BVO have been used legally in some citrus-flavored…  read on >  read on >

A new drug to treat Alzheimer’s disease was approved by the U.S. Food and Drug Administration on Tuesday. In clinical trials, donanemab (Kisunla) modestly slowed the pace of thinking declines among patients in the early stages of the memory-robbing disease. But it also carried significant safety risks, including swelling and bleeding in the brain. “Kisunla…  read on >  read on >